Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects
Donghoon Shin,1 Younsoo Kim,1 Ahra Go,1 Maria Velinova2 1Samsung Bioepis Co., Ltd., Incheon, Republic of Korea; 2PRA International, Groningen, the NetherlandsCorrespondence: Donghoon ShinSamsung Bioepis Co., Ltd, 107, Cheomdan-daero, Yeonsu-gu, Incheon 21987, Republic of KoreaTel +82-31-8061-4534Fax...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-01-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/comparison-of-the-pharmacokinetics-safety-and-tolerability-of-the-auto-peer-reviewed-article-DDDT |
| _version_ | 1818309844674805760 |
|---|---|
| author | Shin D Kim Y Go A Velinova M |
| author_facet | Shin D Kim Y Go A Velinova M |
| author_sort | Shin D |
| collection | DOAJ |
| description | Donghoon Shin,1 Younsoo Kim,1 Ahra Go,1 Maria Velinova2 1Samsung Bioepis Co., Ltd., Incheon, Republic of Korea; 2PRA International, Groningen, the NetherlandsCorrespondence: Donghoon ShinSamsung Bioepis Co., Ltd, 107, Cheomdan-daero, Yeonsu-gu, Incheon 21987, Republic of KoreaTel +82-31-8061-4534Fax +82-31-8061-4393Email dh01.shin@samsung.comPurpose: SB4 is an etanercept biosimilar, approved by the European Commission (EC) and the US Food and Drug Administration (FDA) following a demonstration of equivalent efficacy and safety and comparable quality data to the reference product. This study aimed to demonstrate equivalent pharmacokinetic (PK) profiles, safety, and tolerability between SB4 autoinjector (AI) and SB4 pre-filled syringe (PFS).Patients and methods: This was an open-label, two-period, two-sequence, single-dose, cross-over study to evaluate bioequivalence of PK profiles, safety, and tolerability between SB4 AI and PFS in healthy adults. Treatment periods were separated by 14 days resulting in a 35-day washout between investigational product (IP) administration in Periods 1 and 2.Results: A total of 50 subjects were randomized: 24 subjects in Sequence I and 26 in Sequence II, and 6 subjects discontinued from the study. The primary PK endpoints including area under the concentration–time curve from time zero to infinity (AUCinf) and to the last quantifiable concentration (AUClast), and maximum serum concentration (Cmax) were all within the equivalence margin of 80.00–125.00%. Safety and tolerability were comparable between the two treatments.Conclusion: PK profiles showed that SB4 AI and PFS were bioequivalent in healthy subjects. Safety assessment was also comparable between the two treatments.Keywords: biosimilar, etanercept, bioequivalence, autoinjector, pre-filled syringe |
| first_indexed | 2024-12-13T07:36:38Z |
| format | Article |
| id | doaj.art-af2c73ff2e174a38a8509b7cc39be77b |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-13T07:36:38Z |
| publishDate | 2020-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-af2c73ff2e174a38a8509b7cc39be77b2022-12-21T23:55:04ZengDove Medical PressDrug Design, Development and Therapy1177-88812020-01-01Volume 14435050968Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy SubjectsShin DKim YGo AVelinova MDonghoon Shin,1 Younsoo Kim,1 Ahra Go,1 Maria Velinova2 1Samsung Bioepis Co., Ltd., Incheon, Republic of Korea; 2PRA International, Groningen, the NetherlandsCorrespondence: Donghoon ShinSamsung Bioepis Co., Ltd, 107, Cheomdan-daero, Yeonsu-gu, Incheon 21987, Republic of KoreaTel +82-31-8061-4534Fax +82-31-8061-4393Email dh01.shin@samsung.comPurpose: SB4 is an etanercept biosimilar, approved by the European Commission (EC) and the US Food and Drug Administration (FDA) following a demonstration of equivalent efficacy and safety and comparable quality data to the reference product. This study aimed to demonstrate equivalent pharmacokinetic (PK) profiles, safety, and tolerability between SB4 autoinjector (AI) and SB4 pre-filled syringe (PFS).Patients and methods: This was an open-label, two-period, two-sequence, single-dose, cross-over study to evaluate bioequivalence of PK profiles, safety, and tolerability between SB4 AI and PFS in healthy adults. Treatment periods were separated by 14 days resulting in a 35-day washout between investigational product (IP) administration in Periods 1 and 2.Results: A total of 50 subjects were randomized: 24 subjects in Sequence I and 26 in Sequence II, and 6 subjects discontinued from the study. The primary PK endpoints including area under the concentration–time curve from time zero to infinity (AUCinf) and to the last quantifiable concentration (AUClast), and maximum serum concentration (Cmax) were all within the equivalence margin of 80.00–125.00%. Safety and tolerability were comparable between the two treatments.Conclusion: PK profiles showed that SB4 AI and PFS were bioequivalent in healthy subjects. Safety assessment was also comparable between the two treatments.Keywords: biosimilar, etanercept, bioequivalence, autoinjector, pre-filled syringehttps://www.dovepress.com/comparison-of-the-pharmacokinetics-safety-and-tolerability-of-the-auto-peer-reviewed-article-DDDTbiosimilaretanerceptbioequivalenceautoinjectorpre-filled syringe |
| spellingShingle | Shin D Kim Y Go A Velinova M Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects Drug Design, Development and Therapy biosimilar etanercept bioequivalence autoinjector pre-filled syringe |
| title | Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects |
| title_full | Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects |
| title_fullStr | Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects |
| title_full_unstemmed | Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects |
| title_short | Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects |
| title_sort | comparison of the pharmacokinetics safety and tolerability of the autoinjector ai and pre filled syringe pfs of sb4 in healthy subjects |
| topic | biosimilar etanercept bioequivalence autoinjector pre-filled syringe |
| url | https://www.dovepress.com/comparison-of-the-pharmacokinetics-safety-and-tolerability-of-the-auto-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT shind comparisonofthepharmacokineticssafetyandtolerabilityoftheautoinjectoraiandprefilledsyringepfsofsb4inhealthysubjects AT kimy comparisonofthepharmacokineticssafetyandtolerabilityoftheautoinjectoraiandprefilledsyringepfsofsb4inhealthysubjects AT goa comparisonofthepharmacokineticssafetyandtolerabilityoftheautoinjectoraiandprefilledsyringepfsofsb4inhealthysubjects AT velinovam comparisonofthepharmacokineticssafetyandtolerabilityoftheautoinjectoraiandprefilledsyringepfsofsb4inhealthysubjects |